KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Other Accumulated Expenses (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Other Accumulated Expenses for 17 consecutive years, with $141.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 3.74% to $141.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $141.7 million, a 3.74% decrease, with the full-year FY2025 number at $141.7 million, down 3.74% from a year prior.
  • Other Accumulated Expenses was $141.7 million for Q4 2025 at Bio-Rad Laboratories, up from $127.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $212.7 million in Q2 2022 to a low of $127.8 million in Q3 2025.
  • A 5-year average of $159.3 million and a median of $154.9 million in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 275.7% in 2021, then fell 20.98% in 2023.
  • Bio-Rad Laboratories' Other Accumulated Expenses stood at $127.9 million in 2021, then surged by 32.6% to $169.6 million in 2022, then dropped by 4.74% to $161.6 million in 2023, then fell by 8.91% to $147.2 million in 2024, then dropped by 3.74% to $141.7 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Other Accumulated Expenses are $141.7 million (Q4 2025), $127.8 million (Q3 2025), and $175.0 million (Q2 2025).